Pronostic, quality of life .....
Long-term estimate of
quality-adjusted life expectancy for nilotinib and imatinib as first-line
treatment for newly diagnosed patients with Philadelphia chromosome-positive
(Ph+) chronic myeloid leukemia in the chronic phase (CML-CP).
June 2011, 2011 ASCO Annual Meeting
CML Patients Taking Imatinib Have Similar Mortality Rates to People in General Population - Pronostic
March 23, 2011, Journal of the National Cancer Institute
CML Patients on Imatinib Live as Long as General Population
March 22, 2011, Medscape Today
Living With a Formerly Fatal Blood Cancer
January 18, 2010, The New York Times
June 2011, 2011 ASCO Annual Meeting
CML Patients Taking Imatinib Have Similar Mortality Rates to People in General Population - Pronostic
March 23, 2011, Journal of the National Cancer Institute
CML Patients on Imatinib Live as Long as General Population
March 22, 2011, Medscape Today
Living With a Formerly Fatal Blood Cancer
January 18, 2010, The New York Times
